Efineptakin alfa
Also known as: efineptakin, GX-I7, NT-I7, rhIL-7-hyFc
Source Efineptakin alfa at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Efineptakin alfa (NT-I7, rhIL-7-hyFc) is a long-acting recombinant human IL-7 fused to a hybrid Fc domain, developed by NeoImmuneTech. It is under investigation for treating lymphopenia, enhancing immune reconstitution, and augmenting anti-tumor immune responses, particularly in combination with checkpoint inhibitors and as an adjunct in COVID-19 and cancer immunotherapy.
Mechanism of Action
Recombinant human IL-7 analog that binds IL-7 receptor (IL-7Rα/CD127) on T lymphocytes, promoting T-cell survival, proliferation, and differentiation. Enhances thymopoiesis and peripheral T-cell expansion, restoring immune function in lymphopenic or immunocompromised states.
Routes of Administration
Goals & Uses
- HIV-associated immune deficiencyInfectious Disease / ImmunologyLow
- Sepsis-induced immunosuppressionCritical Care / ImmunologyLow
- Glioblastoma multiforme (GBM)OncologyLow
- Cancer immunotherapy augmentationOncologyModerate
- Immune reconstitution in lymphopeniaImmunologyModerate
- COVID-19 lymphopenia treatmentInfectious DiseaseModerate
Contraindications
- Known hypersensitivity to efineptakin alfa or componentsAllergy/HypersensitivityHigh
- Organ transplant recipients on immunosuppressionTransplantHigh
- Lymphoma or other T-cell malignanciesOncologyHigh
- Active autoimmune diseaseAutoimmunityHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Skin rash / urticariaDermatologicalUncommon
- Flu-like symptoms / systemic reactionsSystemicCommon
- Transient eosinophiliaHematologicalCommon
- SplenomegalyHematologicUncommon
- LymphadenopathyLymphoreticularUncommon
Drug Interactions
- Systemic corticosteroidsModerate
- Cytotoxic chemotherapyModerate
- Immunosuppressive agents (e.g., tacrolimus, cyclosporine)High
- Anti-PD-1/PD-L1 checkpoint inhibitors (e.g., pembrolizumab, nivolumab)Low
Population Constraints
- Severe hepatic or renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Patients with active malignant T-cell disordersOncologicalAbsolute
Regulatory Status
- European UnionInvestigationalUnder clinical investigation; no EMA marketing authorization.
- United StatesInvestigationalFDA Fast Track designation for multiple oncology indications including GBM. Multiple active IND-supported Phase I/II trials.
- United KingdomInvestigationalNo MHRA approval; investigational use only.
Granted Fast Track designation by the US FDA for multiple oncology indications. Not yet approved in any jurisdiction; multiple Phase I/II clinical trials ongoing globally.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Efineptakin alfa?
Efineptakin alfa (NT-I7, rhIL-7-hyFc) is a long-acting recombinant human IL-7 fused to a hybrid Fc domain, developed by NeoImmuneTech. It is under investigation for treating lymphopenia, enhancing immune reconstitution, and augmenting anti-tumor immune responses, particularly in combination with checkpoint inhibitors and as an adjunct in COVID-19 and cancer immunotherapy.
What is Efineptakin alfa used for?
Efineptakin alfa is educationally associated with: HIV-associated immune deficiency, Sepsis-induced immunosuppression, Glioblastoma multiforme (GBM), Cancer immunotherapy augmentation, Immune reconstitution in lymphopenia, COVID-19 lymphopenia treatment. Educational only — not medical advice.
How is Efineptakin alfa administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Efineptakin alfa?
Reported adverse effects include: Injection site reactions, Skin rash / urticaria, Flu-like symptoms / systemic reactions, Transient eosinophilia, Splenomegaly, Lymphadenopathy. This list is not exhaustive — consult a qualified clinician.
Who should avoid Efineptakin alfa?
Recorded contraindications: Known hypersensitivity to efineptakin alfa or components, Organ transplant recipients on immunosuppression, Lymphoma or other T-cell malignancies, Active autoimmune disease. Consult a qualified clinician before use.